David Alsadius1, Caroline Olsson2, Niclas Pettersson3, Susan L Tucker4, Ulrica Wilderäng2, Gunnar Steineck5. 1. Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden. Electronic address: david.alsadius@oncology.gu.se. 2. Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden. 3. Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Göteborg, Sweden. 4. Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, USA. 5. Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden; Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Abstract
BACKGROUND AND PURPOSE: With modern radiotherapy technology we have the means to substantially reduce late gastrointestinal toxicities after radiation therapy for prostate cancer. However, there is still a lack of knowledge regarding the spectrum of patient-reported gastrointestinal symptoms after such treatment. MATERIALS AND METHODS: We conducted a cross-sectional study using a study-specific questionnaire to survey gastrointestinal symptoms 2-14years after prostate cancer radiation therapy. We included 985 men treated between 1994 and 2006 with primary (EBRT) or salvage (POSTOP) external beam radiation therapy or EBRT and high-dose rate brachytherapy (EBRT BT). We also included 350 non-irradiated population-based controls randomly matched 1:3 for age and area of residence. RESULTS: Survey participation rate was 89% (874/985) for survivors and 73% (243/332) for controls. We found significant increased prevalence ratios for 13/34 symptoms in the primary EBRT group, 10/34 symptoms in the EBRT BT group and 9/34 symptoms in the POSTOP group, several of which have not been described previously. Bother due to these symptoms increased with increasing symptom intensity and was highest for fecal leakage and defecation urgency. CONCLUSIONS: Our results can be used to inform clinical evaluation and future studies of long-term gastrointestinal toxicity after radiotherapy for prostate cancer.
BACKGROUND AND PURPOSE: With modern radiotherapy technology we have the means to substantially reduce late gastrointestinal toxicities after radiation therapy for prostate cancer. However, there is still a lack of knowledge regarding the spectrum of patient-reported gastrointestinal symptoms after such treatment. MATERIALS AND METHODS: We conducted a cross-sectional study using a study-specific questionnaire to survey gastrointestinal symptoms 2-14years after prostate cancer radiation therapy. We included 985 men treated between 1994 and 2006 with primary (EBRT) or salvage (POSTOP) external beam radiation therapy or EBRT and high-dose rate brachytherapy (EBRT BT). We also included 350 non-irradiated population-based controls randomly matched 1:3 for age and area of residence. RESULTS: Survey participation rate was 89% (874/985) for survivors and 73% (243/332) for controls. We found significant increased prevalence ratios for 13/34 symptoms in the primary EBRT group, 10/34 symptoms in the EBRT BT group and 9/34 symptoms in the POSTOP group, several of which have not been described previously. Bother due to these symptoms increased with increasing symptom intensity and was highest for fecal leakage and defecation urgency. CONCLUSIONS: Our results can be used to inform clinical evaluation and future studies of long-term gastrointestinal toxicity after radiotherapy for prostate cancer.
Authors: Jung Hun Oh; Maria Thor; Caroline Olsson; Viktor Skokic; Rebecka Jörnsten; David Alsadius; Niclas Pettersson; Gunnar Steineck; Joseph O Deasy Journal: Methods Inf Med Date: 2016-09-02 Impact factor: 2.176
Authors: Maria Thor; Caroline E Olsson; Jung Hun Oh; Stine E Petersen; David Alsadius; Lise Bentzen; Niclas Pettersson; Ludvig P Muren; Ann-Charlotte Waldenström; Morten Høyer; Gunnar Steineck; Joseph O Deasy Journal: Acta Oncol Date: 2015-09-04 Impact factor: 4.089